

Amisulpride

가 D₂ 가 , 가 ,
D₂ 가 ,
가 D₂ 가 , amisulpride
가 D₂ (3-5) 가 , amisulpride
가 amisulpride

1. 순수 도파민성 약물인 amisulpride

amisulpride D₂ D₃
peridol chlorpromazine D₂ halo-
D₂ .
D₂ D₂
가 amisulpride가
D₂ 가
가 D₁
가 amisulpride D₃ 가
D₃ 가
가 , 5-HT receptor 가
amisulpride
amisulpride가 5-HT
dopamine
amisulpride가 dopamine

2. 급성기 정신분열병 환자에서 amisulpride의 단기 효과

amisulpride 1~3
ami-
sulpride 가

1) 정신병적 증상과 일반적 정신병리에 대한 효과

amisulpride
amisulpride
amisulpride, haloperidol, -flupenthi-
xol, risperidone, olanzapine amisulpride
(1)
haloperidol(16 mg/day) 가 amisulpride
(100, 400, 800, 1200 mg/day) 가
가 Puech⁸⁾
, 800 mg 가
haloperidol
가 amisulpride
amisulpride
amisulpride
consensus guideline

Amisulpride

(16,17) 가 .
 (18) . SANS
 () , amisulpride
 , clozapine .²¹⁾ Andreason OI-
²²⁾ sen .
 risperidone .¹⁹⁾ olanzapine pride 100 mg amisulpride 300 mg, 가
 6 . 가 6
^{16,20)} 가 , 가
 . amisulpride (23%) subscale SANS (40%)
 가 .
 . amisulpride ,
 , 가 ,²³⁾ 3
 , amisulpride(50 mg
 100 mg) . 가 가 ami-
 2 . sulpride . 가
 가 .
 amisulpride 가 .
3) 정신분열병의 유지치료로서의 amisulpride
 amisulpride
 가 . 4
 12 , haloperidol
 risperidone 가 . 가 12
 가 .²⁾
 amisulpride 50~100 mg 6 ami-
 .⁷⁾ (1)
 , MADRS(Montgomery Asberg Depression Ra- amisulpride haloperi-

dol

24)

amisulpride(10~33 mg/day ; N=118) haloperidol 4 , 50%

amisulpride가 PANSS 65% 52% (p=0.036), CGI

BPRS PANSS 77% 65% (p=0.042).

haloperidol

amisulpride

(2)

25)

amisulpride(200~800 mg/day ; N=370) haloperidol pride 가, Loo 2) amisulpride(100 mg) 6 amisulpride(5~20 mg/day ; N=118) 1 가 가 가

amisulpride ha- BPRS PANSS 가 가

haloperidol PANSS 가 가

amisulpride 가 가 가

haloperidol 가 가 가

AIMS 가 가 가

가 가 가

42%

(SANS total>60 ; SAPS total<50). 20% , amisulpride (p=0.0002).

(SAPS 19 22,)

(SAPS 19 21,).

SANS

amisulpride(400~1000 mg/day) risperidone(4~10 mg/day) 가 13) well-being (3) Amisulpride being 가 (BPRS PA-NSS)

2 가 309 , 6

PANSS 가 60

(가)

가

amisulpride가

PANSS BPRS risperidone 가

amisulpride 가

Amisulpride

가 Carriere ²⁴⁾ Colona
²⁵⁾ haloperidol
, Robert ²⁶⁾

. amisulpride
, Quality of Life
Scale(QLS)²⁷⁾ haloperidol

.
가

haloperidol
가

가 Social and Functional Assessment Scale(SOFAS)
risperidone 가 ¹³⁾ SOFAS
(8)

. (180)
risperidone amisulpride
가 risperidone (83%)

amisulpride (93%)
ami-

sulpride Global Assessment of
Functioning Scale(GAF)²⁸⁾ 가

가 ⁴⁾ 12
12% , 5%

risperidone

. Amisulpride

가

. amisulpride가
가

가

sulpride가

가

(risperidone)

중심 단어 : Amisulpride

참고문헌

- 1) Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, et al. Amisulpride: from animal pharmacology to therapeutic action. *Int Clin Psychopharmacol* 1997;12 (Suppl 2):29-36.
- 2) Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. *Br J Psychiatry* 1997;170:18-22.
- 3) Martinot JL, Paillere-Martinot ML, Poirier MF, Dao-Castellana MH, Loc'h C, Maziere B. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. *Psychopharmacology* 1996;124:154-158.
- 4) Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc'h C, et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. *J Clin Psychopharmacol* 2001;21:207-214.
- 5) Xiberas X, Martinot JL, Mallet L, Artiges E, Loc'h C, Maziere B, et al. Extrastriatal and striatal D (2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. *Br J Psychiatry* 2001;179:503-508.
- 6) Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. *Synapse* 1987;1:133-152.

결론

amisulpride

amisulpride

가
, amisulpride

amisulpride

- 7) Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F. *Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry* 1995;152:130-134.
- 8) Puech A, Fleurot O, Rein W. *Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand* 1998;98:65-72.
- 9) Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lemperiere T, et al. *Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia. Neuropsychobiology* 2001;44:41-46.
- 10) Moller HJ, Boyer P, Fleurot O, Rein W. *Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology* 1997;132:396-401.
- 11) Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz WF, Sauer H, et al. *Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology* 1998;137:223-232.
- 12) Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W. *Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res* 1999;88:107-117.
- 13) Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y, The Amisulpride Study Group. *Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month, double-blind study. Neuropsychopharmacology* 2002;27:1071-1081.
- 14) Martin S, Loo H, Peuskens J, Thirumalai S, Giudicelli A, Fleurot O, et al. *A double-blind randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Curr Med Res Opin* 2002;18:355-362.
- 15) Mortimer A, Martin S, Loo H, Peuskens J. *A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol* 2004;19:63-69.
- 16) Tollefson GD, Sanger TM. *Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry* 1997;154:466-474.
- 17) Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF. *Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naïve patients before and after treatment. Am J Psychiatry* 2000;157:1461-1466.
- 18) Leucht S, Pitschel-Walz G, Abraham D, Kissling W. *Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res* 1999;35:51-68.
- 19) Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. *Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry* 1998;155:751-760.
- 20) Moller HJ, Muller H, Borison RL, Schooler NR, Chouinard G. *A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci* 1995;245:45-49.
- 21) Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. *Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry* 1995;166:68-72.
- 22) Andreason NC, Olsen S. *Negative vs positive schizophrenia: definition and validation. Arch Gen Psychiatry* 1982;39:789-794.
- 23) Danion JM, Rein W, Fleurot O. *Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry* 1999;156:610-616.
- 24) Carriere P, Bonhomme D, Lemperiere T. *Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry* 2000;15:321-329.
- 25) Colonna L, Saleem P, Dondey-Nouvel L, Rein W. *Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol* 2000;15:13-22.
- 26) Robert P, Braccini T, Vitali P, Darcourt G. *Psychosocial aptitude rating scale (PARS): presentation and validation. Psychol Med* 1987;19:1761-1765.
- 27) Heinrichs SW, Hanlon TE, Carpenter WT. *The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bull* 1984;10:388-396.
- 28) American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (4th Edn). (American Psychiatric Association: Washington DC, USA):1994.*